VEGFA and monoclonal gammopathy: In addition to the specific and well-known role of monoclonal immunoglobulin deposition as a key factor in kidney lesions in patients with monoclonal gammopathy of renal significance (MGRS) [4] and the recent demonstration of renal toxicity due to the growing use of immune checkpoint inhibitors [5] or anticancer therapies targeting vascular endothelial growth factor (VEGF) [6], clinicians need to be able to recognize other kidney parenchymal lesions occurring in patients with hematologic malignancies, because these lesions may affect prognosis and interfere with optimal management.